TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06469359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal tissue-resident memory T and B cells
Description: Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
Study: NCT06559644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hema-NeoTIL01
Description: Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
Study: NCT06558955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-enabled anticipatory guidance and peer support
Description: The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional health education
Description: Participants on this arm will receive conventional child oral health education materials at 4 time points.
Study: NCT06185491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HGI
Description: Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
Study: NCT05938010

Intervention type: DEVICE
Intervention: Dailies Total1® contact lenses for astigmatism (T30fA)
Description: Dailies Total1® contact lenses for astigmatism (T30fA)
Study: NCT05171335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Arterial Chemoembolization
Description: Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
Study: NCT06469359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal tissue-resident memory T and B cells
Description: Nasal tissue-resident memory T and B cells are quantified using flow cytometry.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal fluid sampling
Description: Nasal fluid is collected using strip (Hunt Development) in both nostrils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal fluid sampling
Description: Nasal fluid is collected using strip (Hunt Development) in both nostrils
Study: NCT04880616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching NBI-827104 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching NBI-827104 for oral administration
Study: NCT06043388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Description: Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
Study: NCT05081102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of oxycodone 5 mg/ibuprofen 400 mg
Description: receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylex
Description: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Study: NCT04863209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper cervical manipulation
Description: The patient will receive an upper cervical manipulation as described in the Experimental Group 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion manipulation
Description: The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
Study: NCT05828511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab will be administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab will be administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab will be administered by intravenous (IV) infusion
Study: NCT06432868

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Solarplast (R)
Description: Daily supplementation for 28 days prior to heavy resistance exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation for 28 days prior to heavy resistance exercise.
Study: NCT04869020

Intervention type: DEVICE
Group type: OTHER
Intervention: Otoband
Description: Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.

Intervention type: DEVICE
Group type: OTHER
Intervention: Otoband
Description: Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham A
Description: Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham B
Description: Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
Study: NCT06060834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Topical Botanical Agent
Description: Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
Study: NCT06469359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal fluid sampling
Description: Nasal fluid is collected using strip (Hunt Development) in both nostrils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Saliva is collected using Oracol (Malvern Medical Developments)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Saliva is collected using Oracol (Malvern Medical Developments)
Study: NCT04479527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
Study: NCT05866263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: green walking and intelligence gam
Description: The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green walking and intelligence gam
Description: The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
Study: NCT05592288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREDIABE-TR mobile app.
Description: * Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity.
Study: NCT05575427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: The patients will receive minocycline oral between 7-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin or Cotrimoxazole
Description: The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin or Cotrimoxazole
Description: The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study: NCT04865458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC89736
Description: HEC89736 tablets QD every 28 days for each cycle
Study: NCT01341548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide nasal solution 0.01%
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Civamide nasal solution 0.01%
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril
Study: NCT06500728

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein and Indocyanine green Angiography
Description: The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein and Indocyanine green Angiography
Description: The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution Optical Coherence Tomography
Description: The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution Optical Coherence Tomography
Description: The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).

Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-Optical Coherence Tomography
Description: The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).

Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-Optical Coherence Tomography
Description: The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
Study: NCT06277830

Intervention type: DEVICE
Intervention: Wearable sensor
Description: Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
Study: NCT05409651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
Study: NCT06258746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK31679
Description: A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
Study: NCT06469359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Saliva is collected using Oracol (Malvern Medical Developments)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA to measure antibody responses in mucosal fluids and blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA to measure antibody responses in mucosal fluids and blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA to measure antibody responses in mucosal fluids and blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neutralization test
Description: Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neutralization test
Description: Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
Study: NCT06281873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure by PRF membrane
Description: Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
Study: NCT06211270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRESH
Description: FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FRESH
Description: FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
Study: NCT05380999

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)
Description: Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
Study: NCT04687618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula withAutomatic control of FiO2 using OAM
Description: The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula with manual control of FiO2
Description: In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
Study: NCT06469359

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neutralization test
Description: Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPot
Description: ELISPot to measure cellular responses in blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPot
Description: ELISPot to measure cellular responses in blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPot
Description: ELISPot to measure cellular responses in blood
Study: NCT06194877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusion via an infusion pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusion via an infusion pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusion via an infusion pump
Study: NCT05839262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical rehabilitation plus Active video games (CPR+AVG)
Description: In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical rehabilitation alone (CPR)
Description: In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility).
Study: NCT05113602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGOnight
Description: EEG dry electrodes portable device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enobio
Description: EEG wet electrodes portable device
Study: NCT05416632

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Athrometer
Description: Arthrometer
Study: NCT05316051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted foot orthoses
Description: Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted foot orthoses
Description: Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.